During their stay in the United States, Mr. and Mrs. Cloves heard that two Canadian scientists, Frederick Wanzin and Charles Best, were treating diabetic patients with insulin extracted from bovine pancreas. Mr. and Mrs. Clough are very interested in this, because Mrs. Clough has diabetes herself. Finally, they got a license to produce insulin in Denmark.
After returning to Denmark, Clough immediately discussed the matter with Professor H C· Hagdorn, an expert on blood sugar regulation, and decided to conduct further research. Then, they visited August Kunst, a Danish pharmacist. August Kunst agreed to pay for the research and help start producing insulin. 1922 65438+February 2 1 day, Professor krogh and Professor H C· Hagdorn successfully extracted a small amount of insulin from bovine pancreas. 1923 In March, the first batch of patients received insulin treatment produced by them. 1923 In the spring, they set up Nord Insulin Laboratory (Nord Company).
1923, Harald Pedersen, an engineer, joined Nord Company to manufacture insulin production machines for the company. Later, his younger brother Thorvald Pedersen was also employed by Nord Company, responsible for the chemical process analysis in insulin production. However, Thorvald Pedersen did not get along well with Hagdorn and was expelled from Hagdorn on 1924. Out of loyalty to brotherhood, harald Peterson submitted his resignation and set up his own company with his brother. At 1924, they also successfully produced insulin. 1925, the two brothers sent a letter to the Danish Pharmacists Association, informing them that Novozil insulin and Novozil syringes were available. The two brothers named their company "Novo and Terapeutisk Lab". At this point, two companies in Denmark will soon become the world's leading insulin manufacturing companies.
In the next 65 years, both companies have achieved rapid development, established large-scale research institutions one after another, and had fierce competition for new products for treating diabetes and occupying the top spot in the market. At the same time, Nord and Novo also began to realize their diversified development by developing other products. Nuohe Company has become the world's largest producer of industrial enzyme preparations, while Nord Company has developed hemophilia treatment drugs and growth care products.
1989 65438+ 10, Novo Nordisk decided to merge and reorganize. At this point, after more than 60 years of competition, the two sides finally opened a new chapter in developing new products for diabetes treatment and fighting in the international market. The new company after the merger is Novo Nordisk.
At the beginning of 1999, Novo Nordisk decided to split the company into two independent operating organizations according to its two core businesses: health care and enzyme preparation. This separation enables the two institutions to have greater freedom of operation and create brilliance in their respective advantageous fields. On June/KOOC-0/65438+/KOOC-0/October/KOOC-0/4, 2000, Novo Nordisk and Novozymes started a new chapter of independent operation.
Novo Nordisk's products have entered the China market since the early 1960s. At the beginning of 1994, Novo Nordisk's board of directors passed the plan of implementing strategic investment in China, established Novo Nordisk (China) Pharmaceutical Co., Ltd. and Biotechnology R&D Center in Beijing, built a modern production factory in Tianjin, and established a national sales network centered on Beijing, Tianjin, Shanghai, Guangzhou, Shenyang, Wuhan, Jinan and Hong Kong. By the end of 2007, the total number of employees in China has exceeded 65,438+0,000.